An overview of the field
Life sciences are a branch of science concerned with the study of living organisms and life processes. An ever developing field and given the demand for innovation in medicine, life science companies are often seeking funding for further research. Thanks to innovations in the investment sphere, there are now many ways for them to go about this task.
According to figures quoted in The Telegraph, early-stage investment into UK life science companies more than tripled between 2015 and 2016. The report goes on to state that despite the instability stemming from the Brexit vote in mid-2016, investment was again expected to increase in 2017.
Life science companies were quick to adopt to equity crowdfunding as a means to raise funds. In 2015, SyndicateRoom was named Europe’s leading online platform for life science investment in a report by Biocom, having funded 16 of the 42 life science projects up to that date. Since then, we have continued to support a number of life science companies, in fact, as of June 2017, 31 percent of all fully funded companies on SyndicateRoom specialised in life sciences. You can view our full portfolio below.
In June 2017, drug company Peptinnovate Limited successfully funded on SyndicateRoom, raising a total of £2,788,130. The company, whose CEO Richard Nagle counts more than 25 years of experience in the pharmaceutical industry, is looking to significantly advance the control and management of moderate to severe chronic inflammatory diseases. You can read more about the raise here.
The SyndicateRoom portfolio
Data correct as of November 2017.
What SyndicateRoom offers investors
SyndicateRoom allows you to invest on the same economic terms as the lead investor. Read more about our model here.
Investors receive the same class of shares no matter how much they invest
Our platform offers you the opportunity to create a diversified portfolio of investments
Previous life science investment opportunities
SyndicateRoom is FREE to join
With SyndicateRoom you gain access to invest alongside professional investors receiving the same share class and same share price.